Pauls Matthew 4

What Happened

• Pauls Matthew, a director of Pelthos Therapeutics (PTHS), sold a total of 786 shares in two transactions on April 2, 2026, generating approximately $16,440 in proceeds.
  • 415 shares sold at a weighted average price of $20.52 for $8,514 (executed across trades at $20.30–$20.78).
  • 371 shares sold at a weighted average price of $21.36 for $7,926 (executed across trades at $21.31–$22.03).
• These were sales (not purchases) and were executed under a pre-arranged Rule 10b5-1 plan to satisfy estimated tax obligations related to the vesting of restricted stock units.

Key Details

• Transaction date: April 2, 2026 (filed April 6, 2026; filing appears timely).
• Transaction type/code: Sale (S) — open market or private sale designation.
• Total shares sold: 786; total proceeds: ~$16,440.
• Price details:
  • Tranche 1: weighted avg $20.52 (trades ranged $20.30–$20.78).
  • Tranche 2: weighted avg $21.36 (trades ranged $21.31–$22.03).
• Footnote: Sales were made pursuant to a Rule 10b5-1 plan adopted Dec 16, 2025, to cover estimated tax obligations from RSU vesting.
• The reporting person offers to provide, upon request, full trade-by-trade details (number of shares and prices).
• Shares owned after the transaction: not disclosed in the supplied filing data.

Context

• Sales done under a 10b5-1 plan are pre-arranged trading plans and are typically used for tax or diversification needs; they are not necessarily an indicator of the director’s current view on the company.
• For retail investors, purchases by insiders tend to be more informative than routine sales tied to tax withholding or pre-set plans.